Introduction

47
The interferon-inducible transmembrane protein BST-2 (HM1.24/CD317/tetherin) 48 potently inhibits the release of viral particles and is counteracted by HIV-1 Vpu, which 49 induces its downregulation from the cell surface (27, 42) . This was demonstrated in PBMCs from infected donors were quick thawed at 37 C and washed with PBS. Cells 
Virus stocks and PBMC infection
172
The macrophage-tropic variant of NL4.3, 51-9, is a recombinant infectious molecular 173 clone containing the StuI-NheI fragment of gp120 (C2 and V3 region) from a primary
174
HIV isolate ligated into the NL4.3 clone (9, 10) and was used for infection of PBMCs.
175
The Vpu-deleted version of p51-9 was generated by exchanging the EcoRI-NheI fragment of pNL4-3 ΔVpu, originally named Udel-1 and originated by Klaus Strebel, to 177 create p51-9 ΔVpu.
178
Viruses used for infection were generated in 293T cells, concentrated, and normalized 179 to equal nanograms of p24 capsid antigen. Wild type and Δvpu viruses were tested for 180 infectivity using a HeLa P4R5-based indicator assay; the viruses had similar 181 infectivity/nanogram of p24.
182
Freshly isolated PBMCs were activated for 3 days with PHA and IL-2, then infected with 
Results
197
BST-2 expression levels on uninfected PBMCs.
198
To determine the expression levels of BST-2 on different leukocyte subsets including 
220
The levels of BST-2 expression were increased during HIV infection, with the greatest 221 increase (compared to uninfected controls) of about 2-3 fold during acute infection (Fig.   222 2A). These relative increases were seen on all cell subsets, but they were greatest
223
(over 3-fold) on CD4-positive T cells, the major host cell for HIV-infection (Fig. 2B) chronic infection or after ART treatment (n=5/6; data not shown).
241
The levels of BST-2 observed in chronically infected patients were also significantly 242 increased compared to uninfected controls, although this increase was not as great as 
277
The TLR 7 agonist imiquimod, as well as the TLR 8 agonist poly U and the TLR 9 fresh, unfrozen cells) (Fig. 5) . We used fold-enhancement rather than absolute values of fluorescent staining intensity for this comparison, because we observed that freeze-306 thawing decreased the staining intensity of BST-2 on all cell subsets (Supl. Fig. 2 ).
307
Samples derived from patients were only available in a frozen state, whereas our in vitro 308 experiments used freshly isolated PBMCs that were not subjected to freeze-thawing.
309
The induction of BST-2 by treatment with IFNα was comparable to the increase 
IFN-treatment overcomes the effect of Vpu
317
We hypothesized that the levels of BST-2 induced on primary cells by IFN might be able 
338
On day one, the release of wild type HIV, which encodes Vpu, was greater than that of 
388
The fold-increase of BST-2 levels during acute infection in vivo is similar to that BST-2 appears to respond to the level of virus production in vivo, as supported by the 401 relative reduction in BST-2 levels that occurs with successful antiviral therapy. BST-2 in response to viral triggering of TLR 7 and 9.
418
The TLR 3 agonist poly I:C LMW, as well as TLR 9 agonist ODN2216 significantly 419 increased BST-2 levels on PBMCs. These levels were similar to those detected during 
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